Sagimet Biosciences (SGMT) EBITDA (2022 - 2026)

Sagimet Biosciences' EBITDA history runs 5 years deep, the most recent figure standing at -$10.8 million for Q1 2026.

• In Q1 2026, EBITDA rose 41.14% year-over-year to -$10.8 million; the TTM figure through Mar 2026 stood at -$43.6 million (up 23.46% YoY), while the FY2025 annual figure was -$51.1 million, down 12.74% from the prior year.
• EBITDA was -$10.8 million for Q1 2026 at Sagimet Biosciences, down from -$9.6 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$6.4 million in Q3 2023 to a low of -$18.3 million in Q1 2025.
• Historically, EBITDA has averaged -$9.8 million across 5 years, with a median of -$8.1 million in 2023.
• Biggest YoY gain for EBITDA was 41.72% in 2025; the steepest drop was 174.88% in 2025.
• A 5-year view of EBITDA shows it stood at -$7.1 million in 2022, then retreated by 14.11% to -$8.1 million in 2023, then slumped by 102.09% to -$16.4 million in 2024, then surged by 41.72% to -$9.6 million in 2025, then declined by 12.51% to -$10.8 million in 2026.
• The last three EBITDA figures came in at -$10.8 million (Q1 2026), -$9.6 million (Q4 2025), and -$12.9 million (Q3 2025), per Business Quant data.